An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
San Francisco, CA
Friday, March 29, 2013
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection, specifically those who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV Infection
- Are currently active in HIV research
This activity is also relevant for other practitioners including nurse practitioners, nurses, physician assistants, pharmacists, and others.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Upon completion of the course, participants will be able to:
- Apply new data to the prevention and management of HIV with antiretroviral therapy
- Describe the interplay between immune activation, HIV latency, and a cure for HIV infection
- Discuss the implications of the patient protection and Affordable Healthcare Act on HIV care
- Determine which HIV-infected patients with hepatitis C virus (HCV) infection are candidates for HCV treatment and design regimens
- Develop strategies for screening and managing non–AIDS-defining cancers in HIV-infected patients
- Define the barriers to effective pain management and the strategies for the treatment of pain in persons with HIV/AIDS
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Family Physicians Credit
This Live activity, 21st Annual Improving the Management of HIV Disease Advanced CME Course, with a beginning date of 03/29/2013, has been reviewed and is acceptable for up to 6.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved provider of continuing education in nursing by ASNA, an accredited provider by the ANCC/Commission on Accreditation. Provider # 5-115. This program is approved for 6.75 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 6.75 hours (0.675 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE # 0761-9999-13-048-L04-P
This activity is funded through independent, educational grants at a national level from commercial organizations that are committed to supporting high-quality continuing medical education (CME). This activity is part of a national effort that includes this and other live CME courses, live course webcasts, Cases on the Web, and Topics in Antiviral Medicine.™ In the interest of an objective, unbiased, balanced, and scientifically rigorous program, the IAS–USA seeks and pools funding from companies with competing products to support the program. These companies have no input into or control over the program content or the selection of faculty. We gratefully acknowledge the support of the companies listed below.
Merck & Co, Inc
Gilead Sciences, Inc